H.C. Wainwright analyst Ananda Ghosh has maintained their bullish stance on STOK stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the potential of Stoke Therapeutics’ lead candidate, zorevunersen, in treating Dravet syndrome. The ongoing open-label extension (OLE) data indicates that zorevunersen could be the first treatment to modify the disease course, showing significant and sustained reductions in seizures and improvements in cognitive and behavioral functions. These results provide a strong foundation for the EMPEROR Phase 3 trial, which is designed with conservative assumptions to ensure robust outcomes.
Furthermore, the drug’s FDA Breakthrough Therapy Designation and an upcoming regulatory meeting suggest a possible expedited approval process. The strength of the long-term safety and efficacy data supports the potential for zorevunersen to achieve a broad label, differentiating it from current standard-of-care treatments. This differentiation, along with the drug’s ability to address the core unmet needs in Dravet syndrome, positions it for premium pricing and rapid market uptake, justifying the Buy rating.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $39.00 price target.